Prasad Krishna, Singh Parminder, Kanabar Kewal, Vijayvergiya Rajesh
Department of Cardiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Department of Cardiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
BMJ Case Rep. 2020 Jan 23;13(1):e232308. doi: 10.1136/bcr-2019-232308.
Pulmonary haemorrhage is a rare but a life-threatening complication of thrombolytic therapy in patients with acute ST-elevation myocardial infarction (MI). It usually presents with anaemia, massive haemoptysis, acute-onset respiratory distress and diffuse bilateral lung infiltrates on imaging. We hereby describe two patients, who had pulmonary haemorrhage following streptokinase therapy for acute MI. The first patient improved with conservative treatment, while the second patient died due to respiratory failure. Streptokinase, a fibrin non-specific agent, is a widely used thrombolytic in low-income and middle-income countries. Pulmonary haemorrhage should be suspected in patients who develop sudden respiratory compromise after receiving thrombolytics, especially streptokinase. The management issues related to this uncommon life-threatening complication have been discussed in this article.
肺出血是急性ST段抬高型心肌梗死(MI)患者溶栓治疗中一种罕见但危及生命的并发症。它通常表现为贫血、大量咯血、急性发作的呼吸窘迫以及影像学上双侧肺弥漫性浸润。我们在此描述两名急性心肌梗死患者在接受链激酶治疗后发生肺出血的病例。第一名患者经保守治疗后病情好转,而第二名患者因呼吸衰竭死亡。链激酶是一种纤维蛋白非特异性药物,在低收入和中等收入国家是广泛使用的溶栓剂。对于接受溶栓治疗尤其是链激酶治疗后出现突然呼吸功能不全的患者,应怀疑有肺出血。本文讨论了与这种罕见的危及生命并发症相关的管理问题。